Literature DB >> 9087491

X-ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity.

J M Karle1.   

Abstract

The crystal and molecular structures and absolute configuration of (-)-halofantrine hydrochloride were determined by X-ray diffraction. The absolute configuration of the single chiral center of (-)-halofantrine was established to be in the S configuration. Thus, (+)-halofantrine, the more cardiotoxic isomer, has the R configuration. The carbon atom adjacent to the aromatic ring has the same configuration in both (+)- halofantrine and quinidine, suggesting a stereospecific component to the cardiotoxicity produced by both agents. The intramolecular N ... O distance is 4.177 +/- 0.006 A (1 A = 0.1 nm), which is close to the N ... O distance found in the crystal structure of (+/-)-halofantrine hydrochloride, even though the N-H group points in opposite directions in racemic halofantrine and (-)-halofantrine. Both the hydroxyl group and the amine group form hydrogen bonds with the chloride anions. The crystallographic parameters for (-)-halofantrine hydrochloride were as follows: chemical formula, C26H31Cl2F6NO+. Cl-; Mr, 492.4; symmetry of unit cell, orthorhombic; space group, P2(1)2(1)2(1); parameters of unit cell, a was 6.290 +/- 0.001 A, b was 13.533 +/- 0.003 A, and c was 30.936 +/- 0.006 A; volume of the unit cell, 2,633.2 +/- 0.7 A(3); number of molecules per unit cell, 4; calculated density, 1.354 g cm(-3); source of radiation, Cu K(alpha) (lambda = 1.54178 A); mu (absorption coefficient), 3.50 mm(-1); F(000) (sum of atomic scattering factors at zero scattering angle), 1,120; room temperature was used; final R (residual index), 4.75% for 2,988 reflections, with absolute value of Fo > 3sigma(F), where Fo is the observed structure factor and F is the structure factor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087491      PMCID: PMC163796     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum.

Authors:  L K Basco; C Gillotin; F Gimenez; R Farinotti; J Le Bras
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

2.  A comparison of the antimalarial activity of the cinchona alkaloids against Plasmodium falciparum in vitro.

Authors:  D L Wesche; J Black
Journal:  J Trop Med Hyg       Date:  1990-06

3.  Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents.

Authors:  J M Karle; R Olmeda; L Gerena; W K Milhous
Journal:  Exp Parasitol       Date:  1993-06       Impact factor: 2.011

4.  Structure of the antimalarial halofantrine hydrochloride.

Authors:  J M Karle; I L Karle
Journal:  Acta Crystallogr C       Date:  1989-08-15       Impact factor: 1.172

5.  Resolution of antimalarial agents via complex formation with alpha-(2,4,5,7-tetranitro-9-fluorenylideneaminooxy) propionic acid.

Authors:  F I Carroll; B Berrang; C P Linn
Journal:  J Med Chem       Date:  1978-04       Impact factor: 7.446

6.  Direct determination of the enantiomers of halofantrine and its pharmacologically active metabolite N-desbutylhalofantrine by high-performance liquid chromatography.

Authors:  H Terefe; G Blaschke
Journal:  J Chromatogr       Date:  1993-06-02

7.  Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand.

Authors:  E F Boudreau; L W Pang; K E Dixon; H K Webster; K Pavanand; L Tosingha; P Somutsakorn; C J Canfield
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

8.  Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria.

Authors:  J E Touze; J Bernard; A Keundjian; P Imbert; A Viguier; H Chaudet; J C Doury
Journal:  Am J Trop Med Hyg       Date:  1996-03       Impact factor: 2.345

Review 9.  Clinical pharmacokinetics of halofantrine.

Authors:  J Karbwang; K Na Bangchang
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

10.  Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand.

Authors:  G Watt; L Loesuttiviboon; K Jongsakul; G D Shanks; C K Ohrt; C Karnasuta; B Schuster; L Fleckenstein
Journal:  Am J Trop Med Hyg       Date:  1994-02       Impact factor: 2.345

View more
  2 in total

1.  The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins.

Authors:  D R Brocks; M Ramaswamy; A I MacInnes; K M Wasan
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

2.  Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.

Authors:  D R Abernethy; D L Wesche; J T Barbey; C Ohrt; S Mohanty; J C Pezzullo; B G Schuster
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.